UNSPSC 51284613: Meropenem trihydrate

This classification denotes a beta-lactam antibiotic with the molecular formula C17H25N3O5S.3H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FV9J3JU8B1, chemically known as 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-((dimethylamino)carbonyl)-3-pyrrolidinyl)thio)-6-(1-hydroxyethyl)-4-methyl-7-oxo-, trihydrate, (4r-(3(3s*,5s*),4alpha,5beta,6beta(r*)))- but more generally known as meropenem, which bears US NIH Compound Identifier 60706.

UNSPSC 51284613 Meropenem trihydrate, a Commodity code, shows minimal recent activity directly aligned with its pharmaceutical scope. The source records four state and local opportunities posted between January and June 2026, yet none specifically target meropenem or other branded or generic antibiotics by name. Instead, the opportunities span naloxone procurement (Seminole County, Florida), a Texas HHS exploratory RFI on direct-to-manufacturer prescription programs, Tampa Fire Department medical and first aid supplies, and a Minnesota multistate cooperative purchasing RFP for generic pharmaceuticals and OTC products. Only the Minnesota MMCAP cooperative and Texas HHS initiatives touch pharmaceutical procurement at scale, and neither identifies meropenem or other specific antibiotic products as line items in the available documentation.

State and local buyers acquiring pharmaceutical products do so through large cooperative purchasing vehicles — MMCAP serving Minnesota and multiple states including Oregon — and through state health agencies conducting market research on direct-to-manufacturer contracting models. The Tampa Fire Department procurement emphasizes medical consumables and emergency response supplies rather than systemic pharmaceuticals. When state and local governments do procure generic pharmaceuticals, they route purchases through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and require vendors to meet cGMP and DSCSA compliance, maintain insurance thresholds of $2 million to $5 million depending on coverage type, and accept 3 percent administrative fees. The MMCAP RFP, due March 26, 2026, weighted price competitiveness at 75 percent and required NDC-level product specifications and wholesaler relationship documentation. No recent opportunities in the block explicitly solicit meropenem trihydrate by name, NDC code, or therapeutic class, signaling that this code may see limited recent state and local procurement activity or that buyers are classifying antibiotic acquisitions under higher-tier pharmaceutical family or segment codes rather than at the commodity level.